There were two cases of BRAF mutation other than V600E, comprising 0.5% of all non-small cell carcinoma, 0.8% of adenocarcinoma and non-small cell carcinoma without EGFR/ALK aberrations and 1.5% of adenocarcinoma without EGFR/ALK aberrations (Table 6). This evidence concerns the gene ALK and adenocarcinoma.